Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference Transcript
Good morning, everyone, grab your seats. Mani Foroohar, Managing Director here at SVB Leerink covering joint medicine. And I'm very happy to introduce Barry Greene from Alnylam Pharmaceuticals to give us a quick overview and have a little chat. Barry, you want to start us off?
Yes. Mani, thanks for having us, and we'd like to thank the organizers of Leerink for having us here today. It's always a pleasure to give an update on the tremendous progress that we're making in translating RNAi into a whole new class of drugs.
And let me provide a quick kind of 3-, 4-minute overview, and then we can get into the questions.
So as you all know, Alnylam was founded about 16 years ago to develop RNA interference to an entirely new class of drugs. And last year, as you're well aware, we launched our first commercial drug, ONPATTRO. We'll talk more about that. The launch is going extremely
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
